Applicants must submit: (1) requests
for revision of the regulatory review period under 21 CFR 60.25;
(2) due diligence petitions under 21 CFR 60.30; and requests for
hearings under 21 CFR 60.40 regarding decisions on the
petitions.
US Code:
35
USC 156 Name of Law: Generic Animal Drug and Patent Term
Restoration Act of 1988
US Code: 21
USC 355(j) Name of Law: Drug Price Competition and Patent Term
Restoration Act of 1984
Originally, the ICR submitted
three years ago was submitted and/or lumped together as 1 IC, but,
in reality there are 3 ICs. The submission of this ICR package will
show in Part 2 each IC, and so the number of submissions and
respondents under this information collection remains the
same.
$1,200
No
No
No
No
No
Uncollected
ILa Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.